Warning: error_log(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/bdurrell/public_html/assetise.com/error/error.php on line 115 Warning: error_log(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/bdurrell/public_html/assetise.com/error/error.php on line 115 Warning: error_log(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/bdurrell/public_html/assetise.com/error/error.php on line 115 Warning: error_log(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/bdurrell/public_html/assetise.com/error/error.php on line 115 Warning: error_log(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/bdurrell/public_html/assetise.com/error/error.php on line 115 [Noah's Classifieds] - (ARFORMOTEROL TARTRATE) INHALATION SOLUTION IN PEOPLE WITH MODERATE
Please register or log in.
Item details add to favorites
Category Cars
No Picture
Created 2019-10-24
Owner freemexy
Title (ARFORMOTEROL TARTRATE) INHALATION SOLUTION IN PEOPLE WITH MODERATE
Description (ARFORMOTEROL TARTRATE) INHALATION SOLUTION IN PEOPLE WITH MODERATE Sunovion Pharmaceuticals Inc. (Sunovion) today announced that new analyses of clinical and health outcomes data for Brovana® (arformoterol tartrate) Inhalation Solution will be presented at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13-18, 2016 in San Francisco, Calif. The company will present post-hoc analyses using data from a long-term safety study evaluating BROVANA use in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). Results from a prospective health outcomes study assessing the prevalence of low peak inspiratory flow rate among real world COPD patients will also be presented at the meeting.Arformoterol tartrate powder “COPD is a chronic and progressive disease affecting more than 15 million adults in the U.S. and is the third leading cause of death in the U.S.,” said Krithika Rajagopalan, Vice President, Head of Global Health Economics and Outcomes Research, Sunovion. “COPD exacerbations adversely impact a person’s quality of life, and also impose a substantial economic burden on the health system. Our aim is to provide treatments that can improve health outcomes for the COPD community, and the data being presented at ATS showcases Sunovion’s continued commitment to providing safe and effective treatment options for people with COPD.” BROVANA Health Economics and Outcomes Research (HEOR) Data Presented at ATS: Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate – Poster #A6833, Board P63; Wednesday, May 18, 2016, 11:00 a.m. – 12:45 p.m., at Area A, Hall D (Lower Level), North Building, Moscone Center. Chronic Obstructive Pulmonary Disease (COPD) - Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study – Poster #A1122, Board 1017; Sunday, May 15, 2016, 9:00 a.m. – 11:00 a.m., at Room 3024 (3rd Level), West Building, Moscone Center. Additional HEOR Data Presented at ATS: Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in Chronic Obstructive Pulmonary Disease (COPD) Patients At Discharge After an Exacerbation – Poster Board #A1506, Board P176; Sunday, May 15, 2016, 11:00 a.m. – 12:45 p.m., at Area B, Hall D (Lower Level), North Building, Moscone Center. About COPD Chronic obstructive pulmonary disease, also known as COPD, includes chronic bronchitis and emphysema, and is a progressive respiratory disease that causes worsening obstruction to airflow in the lungs over time.2 Approximately 15.7 million adults in the U.S. report that they have been diagnosed with COPD.3 It is estimated that several million more adults have undiagnosed COPD.4 COPD is responsible for over 120,000 deaths per year, making it the third leading cause of death in the U.S.3 COPD develops slowly and the symptoms often worsen over time, potentially limiting the ability to perform routine activities.1 Symptoms of COPD include constant coughing, wheezing, shortness of breath, excess production of mucus in the lungs, the inability to breathe deeply and the feeling of being unable to breathe.3 About Brovana® (arformoterol tartrate) Inhalation Solution Brovana® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.
Consumption  
Broken No
Price  
Promotion level None
Reply to this posting
Email this to a friend